SHC Stock Overview
Engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Sotera Health Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.44 |
| 52 Week High | US$17.44 |
| 52 Week Low | US$10.71 |
| Beta | 2.06 |
| 11 Month Change | 16.79% |
| 3 Month Change | 32.65% |
| 1 Year Change | -3.50% |
| 33 Year Change | -40.34% |
| 5 Year Change | n/a |
| Change since IPO | -38.49% |
Recent News & Updates
Recent updates
Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable
Sep 02
Sotera Health (NASDAQ:SHC) Takes On Some Risk With Its Use Of Debt
Jun 25Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 30The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%
Mar 21Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models
Mar 01McIntyre Partnerships - Sotera Health Company: A Notable Outlier At A Discount
Feb 08Is Sotera Health (NASDAQ:SHC) A Risky Investment?
Feb 06Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump
Dec 28Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price
Dec 11An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued
Sep 10Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate
Jun 05Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?
Feb 13Market Participants Recognise Sotera Health Company's (NASDAQ:SHC) Earnings Pushing Shares 29% Higher
Nov 24Sotera Health plunges 20% after jury awards $363M against its Sterigenics unit
Sep 19Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 49%?
Sep 08Sotera Health GAAP EPS of $0.11 misses by $0.05, revenue of $266.64M beats by $10.34M
Aug 04Is Sotera Health Company (NASDAQ:SHC) Trading At A 46% Discount?
May 09Shareholder Returns
| SHC | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -1.2% | 1.0% | 0.5% |
| 1Y | -3.5% | 2.8% | 22.7% |
Return vs Industry: SHC underperformed the US Life Sciences industry which returned 2.8% over the past year.
Return vs Market: SHC underperformed the US Market which returned 22.7% over the past year.
Price Volatility
| SHC volatility | |
|---|---|
| SHC Average Weekly Movement | 4.9% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SHC's share price has been volatile over the past 3 months.
Volatility Over Time: SHC's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3,000 | Michael Petras | soterahealth.com |
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.
Sotera Health Company Fundamentals Summary
| SHC fundamental statistics | |
|---|---|
| Market cap | US$4.37b |
| Earnings (TTM) | US$39.94m |
| Revenue (TTM) | US$1.10b |
109.5x
P/E Ratio4.0x
P/S RatioIs SHC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SHC income statement (TTM) | |
|---|---|
| Revenue | US$1.10b |
| Cost of Revenue | US$492.21m |
| Gross Profit | US$605.97m |
| Other Expenses | US$566.04m |
| Earnings | US$39.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 55.18% |
| Net Profit Margin | 3.64% |
| Debt/Equity Ratio | 526.2% |
How did SHC perform over the long term?
See historical performance and comparison